Gland Pharma Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC). The company announced this regulatory milestone through an official press release filed under Regulation 30 with the stock exchanges.

Product Specifications and Market Position

The approved formulation is bioequivalent and therapeutically equivalent to the reference listed drug Lumify Ophthalmic Solution, 0.025%, manufactured by Bausch & Lomb Inc. The product is indicated to relieve redness of the eye and represents an important addition to Gland Pharma's ophthalmic portfolio.

Market Opportunity

According to IQVIA data, the product generated US sales of approximately $39 million for the twelve months ending September 2025. This substantial market size highlights the commercial potential for Gland Pharma's generic version once it receives final approval and launches commercially.

Regulatory Compliance

The company filed the announcement with BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Company Secretary and Compliance Officer Sampath Kumar Pallerlamudi signed the regulatory filing.

Strategic Implications

This tentative approval strengthens Gland Pharma's position in the ophthalmic segment and demonstrates the company's continued capability in developing complex generic formulations. As a generic injectable and ophthalmic-focused pharmaceutical company with a global footprint across 60 countries, this approval aligns with the company's strategic focus on sterile injectables and specialized therapeutic areas.

Gland Pharma has announced a significant leadership change with the resignation of Mr. Shyamakant Giri from his position as Chief Executive Officer. The pharmaceutical company disclosed this development in a regulatory filing dated March 03, 2026, in compliance with SEBI listing regulations.

Resignation Details

Mr. Giri submitted his resignation letter on February 24, 2026, formally stepping down from his role as CEO and Key Management Personnel. The Board of Directors accepted his resignation on March 03, 2026, following a recommendation from the Nomination and Remuneration Committee.

Transition Timeline

The resignation will become effective from the close of business hours on April 30, 2026. This timeline provides the company with approximately two months to manage the leadership transition and ensure continuity in operations.

Board's Response

In the official communication to stock exchanges, the Board of Directors and the entire Gland Pharma family placed on record their sincere appreciation for Mr. Giri's leadership and contribution as CEO. The resignation letter indicates that Mr. Giri's decision came after careful consideration, as he looks to pursue new opportunities.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided all required details as per regulatory guidelines, including the resignation letter and relevant annexures to both BSE and NSE.

Company Leadership

The regulatory filing was signed by Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer, ensuring proper documentation and disclosure of this key management personnel change. The company has committed to ensuring a smooth transition during this leadership change.